These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23813283)

  • 21. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
    Tomaras GD; Plotkin SA
    Immunol Rev; 2017 Jan; 275(1):245-261. PubMed ID: 28133811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial.
    Kijak GH; Tovanabutra S; Rerks-Ngarm S; Nitayaphan S; Eamsila C; Kunasol P; Khamboonruang C; Thongcharoen P; Namwat C; Premsri N; Benenson M; Morgan P; Bose M; Sanders-Buell E; Paris R; Robb ML; Birx DL; De Souza MS; McCutchan FE; Michael NL; Kim JH
    J Virol; 2013 Jul; 87(13):7265-81. PubMed ID: 23576510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV Vaccine Efficacy Trials: RV144 and Beyond.
    Heger E; Schuetz A; Vasan S
    Adv Exp Med Biol; 2018; 1075():3-30. PubMed ID: 30030787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
    Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inferences on relative failure rates in stratified mark-specific proportional hazards models with missing marks, with application to HIV vaccine efficacy trials.
    Gilbert PB; Sun Y
    J R Stat Soc Ser C Appl Stat; 2015 Jan; 64(1):49-73. PubMed ID: 25641990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoprofiling Correlates of Protection Against SHIV Infection in Adjuvanted HIV-1 Pox-Protein Vaccinated Rhesus Macaques.
    Lu P; Guerin DJ; Lin S; Chaudhury S; Ackerman ME; Bolton DL; Wallqvist A
    Front Immunol; 2021; 12():625030. PubMed ID: 34046030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Testing and estimation of time-varying cause-specific hazard ratios with covariate adjustment.
    Sun Y; Hyun S; Gilbert P
    Biometrics; 2008 Dec; 64(4):1070-9. PubMed ID: 18355384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimating cumulative probabilities from incomplete longitudinal binary responses with application to HIV vaccine trials.
    Hudgens MG
    Stat Med; 2003 Feb; 22(3):463-79. PubMed ID: 12529875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sieve analysis using the number of infecting pathogens.
    Follmann D; Huang CY
    Biometrics; 2018 Sep; 74(3):1023-1033. PubMed ID: 29238965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.
    Huang Y; Follmann D; Nason M; Zhang L; Huang Y; Mehrotra DV; Moodie Z; Metch B; Janes H; Keefer MC; Churchyard G; Robb ML; Fast PE; Duerr A; McElrath MJ; Corey L; Mascola JR; Graham BS; Sobieszczyk ME; Kublin JG; Robertson M; Hammer SM; Gray GE; Buchbinder SP; Gilbert PB
    PLoS One; 2015; 10(9):e0136626. PubMed ID: 26332672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.
    Robb ML; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Kunasol P; Khamboonruang C; Thongcharoen P; Morgan P; Benenson M; Paris RM; Chiu J; Adams E; Francis D; Gurunathan S; Tartaglia J; Gilbert P; Stablein D; Michael NL; Kim JH
    Lancet Infect Dis; 2012 Jul; 12(7):531-7. PubMed ID: 22652344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.
    Hertz T; Logan MG; Rolland M; Magaret CA; Rademeyer C; Fiore-Gartland A; Edlefsen PT; DeCamp A; Ahmed H; Ngandu N; Larsen BB; Frahm N; Marais J; Thebus R; Geraghty D; Hural J; Corey L; Kublin J; Gray G; McElrath MJ; Mullins JI; Gilbert PB; Williamson C
    Vaccine; 2016 Nov; 34(47):5792-5801. PubMed ID: 27756485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines.
    Longini IM; Datta S; Halloran ME
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Dec; 13(5):440-7. PubMed ID: 8970471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating and Testing Vaccine Sieve Effects Using Machine Learning.
    Benkeser D; Gilbert PB; Carone M
    J Am Stat Assoc; 2019; 114(527):1038-1049. PubMed ID: 31649413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cost-effectiveness of a modestly effective HIV vaccine in the United States.
    Long EF; Owens DK
    Vaccine; 2011 Aug; 29(36):6113-24. PubMed ID: 21510996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.
    Shepherd BE; Gilbert PB; Jemiai Y; Rotnitzky A
    Biometrics; 2006 Jun; 62(2):332-42. PubMed ID: 16918897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models.
    Dimitrov D; Kublin JG; Ramsey S; Corey L
    EBioMedicine; 2015 Dec; 2(12):2062-9. PubMed ID: 26844286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy.
    Datta S; Halloran ME; Longini IM
    Stat Med; 1998 Jan; 17(2):185-200. PubMed ID: 9483728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting Overall Vaccine Efficacy in a New Setting by Re-Calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy.
    Gilbert PB; Huang Y
    Epidemiol Methods; 2016 Dec; 5(1):93-112. PubMed ID: 28154793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.